110.92
前日終値:
$113.08
開ける:
$113.32
24時間の取引高:
1.52M
Relative Volume:
0.64
時価総額:
$222.45B
収益:
$53.22B
当期純損益:
$12.86B
株価収益率:
17.36
EPS:
6.39
ネットキャッシュフロー:
$14.85B
1週間 パフォーマンス:
-2.29%
1か月 パフォーマンス:
+4.72%
6か月 パフォーマンス:
+3.78%
1年 パフォーマンス:
+13.42%
Novartis Ag Adr Stock (NVS) Company Profile
NVS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NVS
Novartis Ag Adr
|
110.89 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
![]()
LLY
Lilly Eli Co
|
775.15 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
154.40 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
![]()
ABBV
Abbvie Inc
|
186.99 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
![]()
NVO
Novo Nordisk Adr
|
66.29 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | ダウングレード | UBS | Buy → Neutral |
2025-02-12 | 開始されました | Morgan Stanley | Underweight |
2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
2024-01-16 | 再開されました | UBS | Buy |
2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
2022-12-05 | アップグレード | Stifel | Hold → Buy |
2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2022-01-10 | 再開されました | Citigroup | Buy |
2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
2021-03-22 | 開始されました | Bernstein | Mkt Perform |
2021-03-10 | ダウングレード | Argus | Buy → Hold |
2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
2021-01-15 | 開始されました | Deutsche Bank | Buy |
2020-09-29 | 開始されました | Berenberg | Buy |
2020-09-10 | アップグレード | UBS | Neutral → Buy |
2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
2019-04-25 | アップグレード | Liberum | Hold → Buy |
2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
2018-12-11 | 再開されました | Jefferies | Buy |
2018-10-09 | 開始されました | Guggenheim | Neutral |
2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Liver Cancer Treatment Market is expected to generate a revenue of USD 8.88 Billion by 2031, Globally, at 13.45% CAGR: Verified Market Research® - GlobeNewswire Inc.
Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar
Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com
Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com
Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ
Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com
FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com
Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com
No room on the ARK? - Morningstar
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Novartis receives Health Canada approval for Fabhalta® oral treatment for adult patients with PNH - Barchart
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):